Corcept Therapeutics announced a leadership transition in its Endocrinology division. Sean Maduck will retire from his role as President of Corcept Endocrinology, effective October 1, 2026. He will be succeeded by Justin Gunn, who currently serves as Vice President of Sales for the company's Oncology division. Mr. Maduck will continue to serve as a senior advisor to ensure a smooth transition.
Key Details
- Succession: Justin Gunn will assume the role of President, Endocrinology on October 1, 2026.
- Consulting Agreement: Mr. Maduck entered into a one-year consulting agreement with a monthly fee of $57,000, effective October 1, 2026.
- Vesting Schedule: During his consulting term, Mr. Maduck's previously awarded and outstanding stock options will continue to vest according to their original schedule.
- Reason for Departure: The company stated the resignation was not due to any disagreement on matters relating to the company’s operations, policies, or practices.